Taxotere® (T) and doxorubicin (D) combination:: A phase II South American study in first line treatment (tt) of metastatic breast cancer (MBC)

被引：2
|
作者：
Vallejos, C
Nunez, P
Orlandi, L
Carranza, H
Fodor, M
Reyes, JM
Majlis, A
Gavilanes, P
Boussard, B
Salas, E
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷
关键词：
D O I：
10.1016/S0959-8049(99)81740-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1324
引用
收藏
页码：S329 / S329
页数：1
相关论文
共 50 条
  • [1] Phase II study of taxotere(R) (docetaxel, D), Doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)
    Nabholtz, JM
    Mackey, JR
    Smylie, M
    Paterson, A
    Noel, D
    AlTweigeri, T
    Delorme, F
    [J]. BREAST, 1997, 6 (05): : P953 - P953
  • [2] Phase II study of Taxotere in advanced or/and metastatic breast cancer as a first or second line of treatment
    Borisova, TA
    Orel, NF
    Pirogova, NA
    Gorbounova, VA
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 28 - 28
  • [3] Final results of a phase II study of Taxotere (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)
    Nabholtz, JM
    Mackey, JR
    Smylie, M
    Paterson, A
    Noel, D
    Al-Twelgeri, T
    Janowska-Wieczorek, A
    Delome, F
    Riva, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S43 - S43
  • [4] Phase II study biweekly paclitaxel, doxorubicin and gemcitabine as first line chemotherapy for metastatic breast cancer (MBC).
    Sanchez-Rovira, P
    González, E
    Porras, I
    Jaén, A
    Medina, B
    Fernández, M
    Mohedano, N
    Lozano, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S52 - S52
  • [5] Phase II study of the combination of docetaxel, capecitabine and carboplatinum as first line therapy in metastatic breast cancer (MBC)
    Mokaddem, Walid
    Kattan, Joseph
    Chahine, Georges
    Nasr, Fadi
    Farhat, Fadi
    Tueni, Elias
    Dagher, Joya
    Younes, Fariha
    Ghosen, Marwan
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 45 - 46
  • [6] A phase I study of the combination of docetaxel (D) and adriamicin (AD) in first line CT treatment of metastatic breast cancer (MBC)
    Dieras, V
    Gruia, G
    Pouillart, P
    Cvitkovic, E
    Gentin, M
    Azli, N
    Riva, A
    Misset, JL
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 935 - 935
  • [7] A Phase II trial of gemcitabine (G) and doxorubicin (D) combination as first line treatment of metastatic breast cancer: preliminary results
    Beldjillali, Y.
    Yamouni, M.
    Benhadji, K.
    Yekrou, D.
    Bahorah, Z.
    Djellali, L.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 130 - 130
  • [8] Sequential treatment with doxorubicin and docetaxel as first-line chemotherapy in metastatic breast cancer (MBC).: Final results of a Phase II GEICAM study
    Alba, E
    Antón, A
    Ribelles, N
    Pérez-Carrión, R
    López-Vega, J
    Llanos, M
    Pelegri, A
    Florián, J
    Menéndez, M
    Godés, M
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S66 - S66
  • [9] Phase II study with paclitaxel (P) and novantrone (N) as first line treatment in metastatic breast cancer (MBC).
    Fontaine, C
    Neyns, B
    Van Erps, J
    Dewaele, A
    De Grève, J
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 37 - 38
  • [10] Taxotere(TM) (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)
    Nabholtz, JM
    Smyllo, M
    Mackey, JR
    Paterson, A
    Noel, D
    AlTwelgerl, T
    Au, D
    Sansregret, E
    Delorme, F
    Riva, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 : 650 - 650
12345